Vivoo has unveiled FlowPad, the world’s first hygienic menstrual pad with an integrated microfluidic diagnostic system, marking a breakthrough in personal health monitoring. Designed to transform menstrual blood into clear, actionable insights on hormone balance and vaginal health, FlowPad delivers clinical-grade data without requiring any change to a user’s daily routine. Already recognised with a CES Innovation Award, FlowPad represents a significant step forward in how women can access, understand, and act on their health data.

At first glance, FlowPad looks and feels like a conventional menstrual pad. Beneath the surface, however, lies a precisely engineered, fully sealed diagnostic architecture capable of analysing menstrual biomarkers with laboratory-level accuracy. By tapping into menstrual blood, one of the most information-rich yet historically underutilised biological resources, FlowPad turns a routine monthly experience into a powerful tool for insight, autonomy, and early detection.

“Women deserve diagnostics that fit their real lives, intuitive, hygienic, and deeply insightful,” said Miray Tayfun, CEO and Co-Founder of Vivoo. “FlowPad demonstrates how an everyday biological process can become a powerful source of knowledge. This is the future of hormone health: accessible, effortless, and truly human-centred.”

FlowPad will be showcased at CES 2026, alongside the commercial version of the Vivoo Smart Toilet, with live demonstrations throughout the show at the Vivoo booth (Venetian Expo, Halls A–D — Booth 54118).

A Scientific Breakthrough, Hidden in Plain Sight

FlowPad is the first menstrual pad to embed a microfluidic diagnostic layer, a technology that passively captures and channels menstrual blood into controlled biomarker zones. This enables detection of clinically relevant indicators, beginning with Follicle-Stimulating Hormone (FSH), a key marker for fertility, ovarian health, and perimenopause transitions.

At its core is a carefully designed, two-layer microfluidic system built for accuracy and repeatability:

• Capillary capture layer: Draws in a precise volume of menstrual fluid while filtering out particulates to ensure clean, consistent analysis.

• Biomarker reaction layer: Contains stabilised reagents that react with hormones such as FSH and LH, producing colourimetric signatures detectable through advanced image-processing analysis.

• App-based interpretation: After use, users simply scan the pad with the Vivoo App, which analyses microchannel patterns, colour shifts, and reaction intensity to deliver personalised, meaningful insights.

Crucially, all diagnostic activity takes place within a completely sealed pad. There is no fluid handling, no swabs, no vials, and no clinic visits, just real health data generated from a product already used every month.

Menstrual Blood as a Diagnostic Goldmine

Traditional hormone testing relies on invasive blood draws, high costs, and carefully timed clinical appointments. FlowPad fundamentally disrupts this model by converting a naturally occurring biological event into a non-invasive, continuously accessible diagnostic opportunity.

Menstrual blood contains a rich spectrum of biomarkers that reflect what is happening across the endocrine system, from fertility and ovarian reserve to cycle regularity, perimenopause transitions, stress responses, inflammation, and long-term metabolic health. With FlowPad, this information is no longer discarded. Instead, it becomes a source of meaningful, recurring health intelligence.

Once scanned, the Vivoo App translates FlowPad’s microfluidic data into clear explanations and personalised insights. This makes the platform valuable for women tracking fertility, those experiencing irregular cycles, individuals in their late twenties through forties as hormonal patterns begin to shift, and anyone navigating the uncertainty of perimenopause. It also opens new possibilities for clinicians, telehealth providers, and researchers by enabling population-scale hormone insights without the friction of conventional testing methods.

AI-Driven Insights and a Connected Health Ecosystem

The Vivoo App does more than simply display results. Its AI engine interprets menstrual biomarkers, maps cycle-specific patterns, and builds longitudinal hormone trends over time. These insights are further enriched by integration with hydration, nutrition, and lifestyle data already supported within the broader Vivoo ecosystem. Users can also securely share results with healthcare professionals when needed.

As Vivoo expands its connected health platform, FlowPad is expected to synchronise with upcoming Smart Bathroom technologies, creating a more complete and continuous picture of women’s health that spans daily habits, monthly cycles, and long-term trends.

FlowPad offers a glimpse into a future where clinical-grade hormone insights are seamlessly embedded into everyday life. With additional biomarkers planned, including LH, estrogen metabolites, cortisol, inflammation markers, iron levels, infection indicators, and vaginal pH, the diagnostic potential of the menstrual cycle is only just beginning to be unlocked.

Pricing and Availability

FlowPad will make its public debut at CES 2026 at Vivoo Booth #54118 (Venetian Expo, Halls A–D).
The estimated price is USD $4–5 per pad, with subscription options and multipack configurations to be announced closer to launch. Early access will prioritise researchers, medical partners, and existing Vivoo users.3511